-
Monday, May 7, 2012 - 1:03pm
EA Could Replace Zynga As 15% of Facebook's Revenue
Analyst Arvind Bhatia of Sterne Agee says he doubts Zynga (NASDAQ: ZNGA) will be 15% of Facebook's (NASDAQ: FB) revenue in the future. Bhatia explains, “Facebook's own revenue is going to continue to grow at a much higher pace than Zynga's revenue.” Bhatia says he believes Electronic Arts (NASDAQ:...
Read More >> -
Sterne Agee Downgrades StanCorp Financial Group to Underperform
Monday, January 9, 2012 - 10:18amSterne Agee has downgraded StanCorp Financial Group (NYSE: SFG) from Neutral to Underperform and has raised the price target to $37.
Read More >> -
Sterne Agee Upgrades SCBT Financial to Buy
Monday, January 9, 2012 - 10:16amSterne Agee has upgraded SCBT Financial (NASDAQ: SCBT) from Neutral to Buy with a $35 price target.
Read More >> -
Sterne Agee Downgrades Reinsurance Group of America to Neutral
Monday, January 9, 2012 - 10:14amSterne Agee has downgraded Reinsurance Group of America (NYSE: RGA) from Buy to Neutral and has a $62 price target.
Read More >> -
Sterne Agee Downgrades Reinsurance Group of America to Neutral
Monday, January 9, 2012 - 10:14amSterne Agee has downgraded Reinsurance Group of America (NYSE: RGA) from Buy to Neutral and has a $62 price target.
Read More >> -
Sterne Agee Initiates PVH at Buy
Monday, January 9, 2012 - 10:11amSterne Agee has initiated coverage on PVH Corporation (NYSE: PVH) with a Buy rating and $85 price target.
Read More >> -
Sterne Agee Maintains Buy, PT of $43 on Charles River Laboratories
Monday, December 5, 2011 - 8:38amSterne Agee reiterates its Buy rating and price target of $43 on Charles River Laboratories (NYSE: CRL) as sentiment around the stock is low. Sterne Agee says, “After meeting multiple investors recently, we believe sentiment towards CRL shares is extremely low, which we attribute to CRL...
Read More >> -
Sterne Agee Maintains Buy, $7 PT on Albany Molecular Research
Monday, December 5, 2011 - 8:33amSterne Agee reiterates its Buy rating and $7 price target on Albany Molecular Research, Inc. (NASDAQ: AMRI) as the current valuation discounts a $200MM business. Sterne Agee says, “In our view, AMRI's current valuation solely reflects the net present value of future Allegra royalties, which we...
Read More >> -
UPDATE: Sterne Agee Downgrades Cash America International to Neutral
Friday, December 2, 2011 - 8:51amA report from Sterne Agee downgrades its rating to Neutral and reiterates its $53 price target on Cash America International (NYSE: CSH). The report states, “On Thursday, following hearings first initiated on October 18th, the Back Bench Business Committee held further hearings on the debt...
Read More >> -
UPDATE: Sterne Agee Upgrades Analog Devices to Buy
Friday, December 2, 2011 - 8:47amA report from Sterne Agee upgrades its rating to Buy with a $42 price target on Analog Devices Inc. (NYSE: ADI). The report states, “A combination of leaner industrial channel inventories and order stabilization into 1Q12 in U.S.-China and a restorationrecovery in communication orders post the...
Read More >>
